In terms of clinical trial design, phase III confirmatory studies incorporating SLFN11 biomarker stratification should be conducted in SCLC, with SLFN11-positive patients serving as the enriched population to systematically evaluate the efficacy and safety of PARP inhibitor combination regimens in first-line treatment, thereby providing definitive evidence for their clinical application. Here, PARP1 is linked to small cell lung carcinoma.